stockrowNovartis AG
NVS Healthcare Drug Manufacturers General
Novartis AG’s revenue for fiscal 2025 (year ended December 2025) was $56.7 billion, up 9.57% from fiscal 2024.
- Revenue
- +4.67%
- EPS
- −69.1%
- Free cash flow
- −17.8%
- Total debt
- +53.9%
Quarter to September 2026, against a year earlier
Follow NVS
Alert me
Novartis AG (NVS) Net income
Novartis AG's net income for fiscal 2025 was $14.0B, up 17.0% from $11.9B in fiscal 2024. Over the twelve months to 30 September 2026 it was $10.0B. Over the past ten years it has ranged from $6.0B (fiscal 2022) to $24.0B (fiscal 2021); the current reading is higher than 91% of that period. Net income has risen for 3 consecutive fiscal years. Novartis AG ranks 6th of 21 Drug Manufacturers General companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $14.0B | 16.99% |
| FY2024 | $11.9B | 39.28% |
| FY2023 | $8.6B | 41.71% |
| FY2022 | $6.0B | (74.81%) |
| FY2021 | $24.0B | 197.58% |
| FY2020 | $8.1B | 12.93% |
| FY2019 | $7.1B | (44.16%) |
| FY2018 | $12.8B | 66.17% |
| FY2017 | $7.7B | 15.00% |
| FY2016 | $6.7B | (4.70%) |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $1.2B | (63.28%) |
| Jun 2026 | $3.3B | 3.20% |
| Mar 2026 | $3.2B | 31.28% |
| Dec 2025 | $2.4B | (38.83%) |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| NVO Novo Nordisk A/S compare | $17.9B |
| JNJ Johnson & Johnson compare | $16.1B |
| AZN AstraZeneca PLC compare | $13.3B |
| ABBV AbbVie Inc. compare | $10.3B |
| NVS Novartis AG | $10.0B |
| AMGN Amgen Inc. compare | $9.4B |
| PFE Pfizer Inc. compare | $4.1B |
| MRK Merck & Co., Inc. compare | $3.2B |
| GILD Gilead Sciences, Inc. compare | −$3.9B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on NVS
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement